版本:
中国

BRIEF-Stemline Therapeutics reports oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno)

Nov 21 Stemline Therapeutics Inc :

* Stemline Therapeutics Inc- sl-701 was found to be safe and well-tolerated

* Stemline Therapeutics Inc- additional clinical data updates are expected next year

* Press release - Stemline Therapeutics announces oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno) Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐